Doctors who prescribe unapproved injectable peptides and the patients who take them explain absent clinical trial data with a single claim: big pharma cannot patent naturally occurring compounds, so no company will spend billions on trials a rival could copy. Euan Black's report, published 10…
Doctors who prescribe unapproved peptides and the patients who take them have a stock answer when asked why those products lack clinical trial data. "It’s because big pharma can’t patent naturally occurring compounds." Euan Black, a health and wellness reporter, published that explanation as the centerpiece of a report at 5.00am on 10 August 2026. The report presents the line as a ready-made rationale used by prescribers and patients, not as an established legal or economic finding, and it neither verifies nor challenges the underlying claim.
The argument has a clear structure. No large pharmaceutical company would spend billions of dollars to take a naturally occurring peptide through clinical trials, because nothing would stop a rival from copying the work once it was done. A competitor could wait for the trial results, file for approval on the strength of the public data, and sell the same molecule without absorbing any of the development cost. Under that logic, the missing evidence base is not a sign that the compounds are unsafe or ineffective. It is a predictable result of a market that cannot return the investment required to generate the evidence.
The peptides at issue are naturally occurring and are described as injectables. The report names no specific peptide products, no manufacturers, no clinical trials, and no regulatory bodies. It attributes the explanation to the people who prescribe and use the compounds, and not to pharmaceutical companies, researchers, or regulators. What the piece documents, in effect, is what patients are told in the clinic and what some prescribers tell themselves. Whether the economics and the patent law actually work as the rationale assumes is a question the report leaves open.
Two numbers define the reported argument: billions of dollars, the sum a large pharmaceutical company would need to spend to run clinical trials on a naturally occurring peptide, and zero, the cost of copying the result at the end. The second number is the one that does the work. Patent protection exists to let a sponsor recover development costs through temporary exclusivity, and when that exclusivity is unavailable, the investment case collapses. The rationale says that is exactly the situation for naturally occurring peptides: no patent, no exclusivity, no trial, no data.
The incentive problem described in the report is a standard free-rider dynamic. A clinical development program for an injectable peptide would require chemistry, manufacturing, and controls work to produce the molecule at scale under good manufacturing practice; preclinical toxicology; phased human studies to establish dosing, safety, and efficacy; and a regulatory submission. That is the work the billions pay for. If a competitor could wait for the public record and then market a copy, the sponsor would be undercut on price from day one.
The report gives no indication of which peptides, which indications, or which markets are at stake, and it offers no independent assessment of whether the patentability claim is accurate. Its contribution is narrower and still useful: it captures, in the words of the people who use it, an argument that circulates whenever the absence of clinical trial data for unapproved peptides comes up.
The biology explains part of the commercial problem. Naturally occurring peptides are short chains of amino acids that act as hormones, growth factors, and signaling molecules. They are potent and specific but also fragile. Peptidases in the blood and tissues degrade them quickly, and their half-lives are often measured in minutes. Oral delivery is all but impossible for most: the gastrointestinal tract contains enzymes that break peptides down, and the molecules are too large and too hydrophilic to cross the intestinal wall efficiently. That is why the peptides in this discussion are injectables. Injectable delivery is often the only route that puts an intact peptide into the circulation.
The same properties that make native peptides difficult as drugs also make them difficult as business propositions. Because the sequence of a naturally occurring peptide is public knowledge, it cannot be protected as a new chemical entity. A company that develops the peptide has no composition-of-matter protection to stop a rival from manufacturing an identical copy. What the developer would own, at best, would be data: toxicology results, clinical findings, manufacturing specifications. And data, under the rationale reported by Black, is exactly what a rival can take for free once it becomes public.
This is the structural reason the unapproved peptide market looks the way it does. Where companies have invested seriously in peptide drugs, they have mostly invested in engineered analogs: modified sequences, novel formulations, conjugates, and other inventions that are not identical to the natural molecule and therefore can be patented. The native molecules, by contrast, remain largely in the space of unapproved products, prescribed on the strength of mechanistic plausibility and anecdotal reports rather than a registered evidence base.
The assertion that big pharma cannot patent naturally occurring compounds is a simplification of a complicated body of law, and the report does not assess whether it is accurate in any specific jurisdiction. The general principle behind it is real. Courts in several major jurisdictions have held that products of nature are not patentable subject matter. In the United States, the Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories and Association for Molecular Pathology v. Myriad Genetics established that naturally occurring products and natural laws cannot be patented as such. The European Patent Convention similarly excludes discoveries from patentability. A peptide exactly as it exists in the human body is, under that principle, not a patentable invention.
The nuance is that few commercial products are sold exactly as the molecule exists in the body. An isolated and purified peptide, a synthetic version with a modified amino acid sequence, a peptide attached to a carrier, a slow-release formulation, or a new method of use: each of these can be eligible for patent protection even when the underlying native sequence is not. The patent argument as stated by doctors and patients therefore sweeps more broadly than the law does. The accurate version of the claim would be that the native molecule itself cannot be patented, while innovators can sometimes secure exclusivity on modified versions.
The report does not go down this path. It names no jurisdictions, cites no statutes or court decisions, and does not ask whether the argument would hold up in, say, the United States, Europe, or Australia. That gap matters because the practical question is not whether a native peptide can be patented in the abstract. It is whether a company could assemble enough patent protection around a specific product, in the markets where it would sell, to justify the billions of dollars the trials would cost. That question is answerable, but it requires a legal analysis the report does not attempt.
For researchers, the argument points to a structural funding problem. If native peptides cannot support the exclusivity that makes commercial trials worthwhile, the evidence base will have to come from somewhere else: government agencies, academic consortia, foundations, or public-private partnerships that do not require a return on investment. Rare disease and neglected disease research offer precedents, where public and philanthropic funding carries trials that commercial sponsors would not take on.
For clinicians, the immediate task is to keep two questions distinct. The patent argument is an explanation for why clinical trial data are absent. It is not evidence that a peptide works, that it is safe, or that a particular dose is appropriate. Unapproved status means the products have not met the safety and efficacy standard of the drug approval pathway, and no economic theory changes that. Prescribers who offer these peptides, and patients who ask about them, should be able to say: the lack of trials may reflect a broken incentive structure, and the compounds may still be effective, but the lack of trials means the effects and risks are not actually known.
The supply chain implications follow from the same economics. When no company with a billion-dollar budget is willing to sponsor development, manufacturing of unapproved peptides shifts to compounding pharmacies, research chemical suppliers, and gray-market vendors operating outside the quality systems of approved drug manufacturing. Identity, purity, sterility, endotoxin content, and dose accuracy are not guaranteed by regulatory oversight in that space. Patients inject those products on the assumption that the vial contains what the label says. The commercial disincentive that explains missing trials also explains missing quality assurance.
The report’s limits should be stated precisely. The quoted explanation comes from doctors who prescribe unapproved peptides and the patients who take them, a collective group that is not individually identified. It does not come from pharmaceutical companies, researchers, or regulators, and the report does not claim that any of those parties endorse the argument. The piece names no specific peptide products, no manufacturers, no clinical trials, and no regulatory bodies. It includes no assessment of whether the patentability claim is legally accurate. It is, on the evidence available, a documentation of a rationale, not a test of one.
Four open questions follow directly, and none is answered in the report:
The conflation to avoid is between explanation and vindication. An economic account of why data are missing says nothing about whether the data, if they existed, would be favorable. Unapproved products have not been shown to be safe and effective through the standard pathway. The patent argument explains the absence of evidence without diminishing the absence. Both things can be true at once: the incentive structure may be broken, and the peptides may still be unproven.
The patent argument is testable, and the way to test it is legal analysis, not assertion. A jurisdiction-by-jurisdiction assessment of patent eligibility for native-sequence peptides would establish whether the free-rider scenario is real or hypothetical in the markets that matter. That analysis would need to cover composition-of-matter claims on the native molecule and on isolated, purified, or synthetically produced versions, as well as the availability of method-of-use, formulation, and combination patents that could protect a commercial investment even if the molecule itself is unpatentable.
The clinical question is equally tractable. A systematic search of clinical trial registries for registered studies of naturally occurring injectable peptides would show what evidence exists and where the gaps are. Surveys of prescribing practice would show which peptides are actually being used, in which populations, for which indications, and at what doses. That descriptive work would convert a general argument about incentives into a specific map of the…
Related reading: Lilly Confirms Q1 2027 Retatrutide BLA After Phase 3 Wins, Tirzepatide tied to lower predicted 10-year CVD risk over 3 years, ALXN2420 Phase 1: GH receptor peptide antagonist lowers IGF-1, Peptide Nanostructures Kill Resistant Bacteria and Restore Meropenem.